Retatrutide
What Is Retatrutide?
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. In clinical trials, it produced unprecedented weight loss results, making it potentially the most effective obesity treatment developed.
Retatrutide Research & Studies
01 Retatrutide, A Trigonal Glp-1, Gip And Glucagon Receptor Agonist, And Its Role In Weight Reduction ▸
Study found retatrutide significantly reduces weight, waist circumference, and BMI in overweight adults while improving cardiometabolic parameters.
View Study (ScienceDirect)02 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial ▸
Retatrutide significantly improved blood sugar control and reduced body weight across various doses, demonstrating higher effectiveness than placebo and dulaglutide.
View Study (ScienceDirect)03 The Effect Of Triple-Hormone-Receptor Agonist Retatrutide, A Novel Medication For Weight Loss, On Blood Pressure ▸
Retatrutide showed potential to significantly lower both systolic and diastolic blood pressure based on phase 2 trials.
View Study (ScienceDirect)04 Retatrutide showing promise in obesity (and type 2 diabetes) ▸
Retatrutide led to significant weight loss over 24 weeks but frequently caused gastrointestinal side effects.
View Study (PubMed)05 A review of an investigational drug Retatrutide, a novel triple agonist agent for the treatment of obesity ▸
Retatrutide, in Phase III trials, has shown promising weight loss results in earlier trials, indicating potential for treating obesity.
View Study (PubMed)Retatrutide User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
Early adopters report dramatic weight loss exceeding semaglutide results. Side effects similar to other GLP-1 agonists. Not yet FDA approved but generating significant interest.
Retatrutide Benefits, Dosage & Side Effects
- Dramatic Weight Loss: Up to 24% body weight reduction in trials.
- Triple Action: Targets GLP-1, GIP, and glucagon receptors.
- Metabolic Improvement: Better glucose control and metabolic health.
- Appetite Suppression: Significant reduction in hunger.
- Potential Superiority: May exceed semaglutide and tirzepatide.
- Most Effective Weight Loss: Highest recorded in clinical trials.
- Dose-Dependent: Higher doses produce greater weight loss.
- Under Development: Still in clinical trials.
- Clinical Trial Doses: 1-12mg weekly in phase 2 trials.
- Weekly Injection: Administered once weekly.
- Dose Titration: Started low and increased gradually.
- GI Effects: Nausea, vomiting, diarrhea common.
- Similar to GLP-1s: Side effect profile comparable to semaglutide.
- Dose-Related: Higher doses mean more side effects.
- Generally Manageable: Most side effects decrease over time.
- Not Yet Approved: Still in phase 3 clinical trials.
- Research Chemical: Available from some peptide suppliers.
- Future Availability: Expected FDA review pending trial completion.
Community Reviews
Share your experience with Retatrutide and help others make informed decisions.
Write a Review
Sign in to leave a review